PF 5175157
Alternative Names: PF-05175157; PF-5175157Latest Information Update: 05 Nov 2023
At a glance
- Originator Pfizer
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Acetyl-CoA carboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 27 Feb 2015 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in USA (PO)
- 27 Feb 2015 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
- 06 Nov 2014 Phase-II development is ongoing in USA